Welcome to our dedicated page for SELECT MEDICAL HOLDINGS SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Select Medical Holdings Corporation SEC filings document the formal disclosures of a NYSE-listed healthcare services company with common stock traded under SEM. Its Form 8-K reports cover operating results and financial condition, material-event disclosures, capital-structure information, employment and compensation-related agreements, and Regulation FD communications.
Proxy materials and annual-meeting filings describe director elections, executive compensation votes, auditor ratification, board-structure proposals, stockholder meeting rights and voting outcomes. The filings also record governance matters and corporate reporting related to Select Medical's hospital and outpatient rehabilitation operations.
Select Medical Holdings (SEM) reported Q3 results with revenue of $1,363,445 thousand, up from $1,271,582 thousand a year ago. Income from continuing operations, net of tax, was $44,180 thousand versus $41,276 thousand, and EPS from continuing operations was $0.23 versus $0.19. Adjusted EBITDA reached $111,655 thousand compared with $103,898 thousand.
By segment, revenue was $609,929 thousand in Critical Illness Recovery Hospitals, $328,607 thousand in Rehabilitation Hospitals, and $325,383 thousand in Outpatient Rehabilitation. For the nine months ended September 30, 2025, revenue was $4,056,196 thousand and income from continuing operations, net of tax, was $176,791 thousand, with EPS from continuing operations of $1.00. Operating cash flow for the period was $282,142 thousand, and capital expenditures were $170,125 thousand. Total debt had a carrying value of $1,772,149 thousand. As of September 30, 2025, SEM had 123,817,591 shares outstanding.
John F. Duggan, Executive Vice President and a director of Select Medical Holdings Corporation (SEM), reported beneficial ownership of 149,575 shares of the issuer's common stock. The filing discloses four grants of restricted stock: three grants of 25,000 shares (granted on November 1 of 2021, 2022 and 2023) and one grant of 50,000 shares (granted April 30, 2024). Each grant includes vesting schedules that generally fully vest on the fourth anniversary of the grant date, with a special one‑third vesting event noted on November 5, 2024, and other customary exceptions.
Select Medical Holdings Corporation (SEM) filed an 8-K reporting leadership changes. The filing references Item 5.02 and Item 7.01 and includes an exhibit: a press release dated September 2, 2025 announcing the appointment of Mr. Mullin as Chief Executive Officer and noting other changes involving long-tenured leaders. The 8-K indicates the company furnished written communications under Regulation FD and provided the press release as Exhibit 99.1. The disclosure signals a formal CEO transition and related leadership adjustments, documented through the company’s required SEC communication channels.
Select Medical Holdings Corp. (NYSE: SEM) filed an 8-K to disclose board-approved amendments that completely restate the company’s bylaws, effective July 30 2025.
Key change: the revised bylaws tighten the advance-notice process for stockholder director nominations and other business in response to the SEC’s universal proxy rules (Rule 14a-19). A nominating stockholder must now:
- State its intent to deliver a proxy statement and form of proxy to holders representing ≥67% of the voting power entitled to vote on director elections, and include all information required by Rule 14a-19.
- Provide evidence that it has actually solicited proxies from holders of at least 67% of outstanding voting power.
The amended bylaws also make assorted clarifying and procedural updates to the company’s existing advance-notice provisions. The full text is filed as Exhibit 3.1.
No financial results, transactions, or earnings data are included in this report.